|
MechanismEPO receptor agonists |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Randomized, Single-blind, Active Comparator Controlled Phase 2 Clinical Study on the Effectiveness, Safety and Pharmacokinetics of Pegerythropoietin Injection (RD01) in Different Medication Schemes for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
A multicenter randomized, single blind, active comparator controlled phase 2 study which is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin Injection (RD01) as maintenance therapy in the treatment of anemia in chronic renal failure patients with hemodialysis
A Phase 1, Randomised, Double-blind, Single-centre, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single S.C. Doses of RD01 (Pegerythropoietin) in Healthy Chinese Subjects
A first-time in human study to investigate the safety, tolerability and pharmacokinetics of RD01 in healthy Chinese subjects
100 Clinical Results associated with Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
0 Patents (Medical) associated with Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
100 Deals associated with Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
100 Translational Medicine associated with Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd